Literature DB >> 8989501

Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs.

J Häggström1, K Hansson, C Kvart, B E Karlberg, O Vuolteenaho, K Olsson.   

Abstract

OBJECTIVE: To investigate activity of the renin-angiotensin-aldosterone system and N-terminal pro-atrial natriuretic peptide (NT-proANP) during development of clinical signs of decompensated mitral valve regurgitation (MR). ANIMALS: 11 Cavalier King Charles Spaniels with advanced MR attributable to chronic valvular disease. PROCEDURE: Dogs were subjected to repeated examinations at 6-month intervals until signs of decompensation had developed (end point). Data acquired at end point were compared with data obtained from examinations 1 year and 1 to 6 months before decompensation. Each examination included physical examination, collection of venous blood, thoracic radiography, and echocardiography.
RESULTS: Echocardiographic measurements of left atrial-to-aortic root ratio and left ventricular end diastolic diameter increased considerably during the study, whereas left ventricular end systolic diameter remained unchanged. The increase in cardiac size was associated with increased plasma concentration of NT-proANP. In contrast, plasma concentrations of aldosterone and angiotensin II were reduced at decompensation (aldosterone compared with the 2 earlier examinations and angiotensin II compared with values obtained 1 to 6 months before), despite decreased plasma protein concentration and hematocrit, suggesting fluid retention. The urine-to-plasma creatinine ratio was reduced at end point. CONCLUSION AND CLINICAL IMPLICATIONS: Early decompensated MR in dogs was not associated with increased circulating renin-angiotensin-aldosterone system activity, which may be caused by increased activity of ANP, and may be important for future therapeutic strategies of MR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989501

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Myocardial performance and its acute response to angiotensin II infusion in fetal sheep adapted to chronic anemia.

Authors:  Leah S Bernard; Jason N Hashima; A Roger Hohimer; David J Sahn; Muhammad Ashraf; Olli Vuolteenaho; Lowell E Davis; Juha Rasanen
Journal:  Reprod Sci       Date:  2011-11-03       Impact factor: 3.060

2.  Ventricular-arterial uncoupling in heart failure with preserved ejection fraction after myocardial infarction in dogs - invasive versus echocardiographic evaluation.

Authors:  Myrielle Mathieu; Bachar El Oumeiri; Karim Touihri; Ielham Hadad; Maryam Mahmoudabady; Philippe Thoma; Thierry Metens; Jozef Bartunek; Guy R Heyndrickx; Serge Brimioulle; Robert Naeije; Kathleen Mc Entee
Journal:  BMC Cardiovasc Disord       Date:  2010-06-29       Impact factor: 2.298

3.  Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.

Authors:  Éva Larouche-Lebel; Kerry A Loughran; Mark A Oyama; Phil F Solter; Danielle S Laughlin; Melissa D Sánchez; Charles-Antoine Assenmacher; Philip R Fox; Ryan C Fries
Journal:  J Vet Intern Med       Date:  2019-06-28       Impact factor: 3.333

4.  Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease.

Authors:  Éva Larouche-Lebel; Kerry A Loughran; Terry Huh; Mark A Oyama
Journal:  J Vet Intern Med       Date:  2020-12-24       Impact factor: 3.175

5.  Response to letter to the editor regarding "Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial".

Authors:  Gerhard Wess; Tony Glaus
Journal:  J Vet Intern Med       Date:  2021-01-26       Impact factor: 3.333

6.  Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.

Authors:  Alberto Galizzi; Mara Bagardi; Angelica Stranieri; Anna Maria Zanaboni; Dario Malchiodi; Vitaliano Borromeo; Paola Giuseppina Brambilla; Chiara Locatelli
Journal:  BMC Vet Res       Date:  2021-01-07       Impact factor: 2.741

7.  A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.

Authors:  Daniel K Newhard; SeungWoo Jung; Randolph L Winter; Sue H Duran
Journal:  J Vet Intern Med       Date:  2018-08-07       Impact factor: 3.333

8.  Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.

Authors:  Mariko Yata; Hans S Kooistra; Niek J Beijerink
Journal:  J Vet Intern Med       Date:  2019-01-31       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.